179 related articles for article (PubMed ID: 11745414)
1. CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Dobashi Y; Noguchi T; Nasuno S; Katayama K; Kameya T
Int J Cancer; 2001 Nov; 94(3):353-62. PubMed ID: 11745414
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
3. Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Noguchi T; Dobashi Y; Minehara H; Itoman M; Kameya T
Am J Pathol; 2000 Jun; 156(6):2135-47. PubMed ID: 10854234
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Shankland SJ; Eitner F; Hudkins KL; Goodpaster T; D'Agati V; Alpers CE
Kidney Int; 2000 Aug; 58(2):674-83. PubMed ID: 10916090
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
[TBL] [Abstract][Full Text] [Related]
6. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Schmidt M; Fan Z
Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
9. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
10. Involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation.
Tian JQ; Quaroni A
Am J Physiol; 1999 Jun; 276(6):C1245-58. PubMed ID: 10362586
[TBL] [Abstract][Full Text] [Related]
11. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
[TBL] [Abstract][Full Text] [Related]
12. Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes.
Go JH
Pathol Res Pract; 2002; 198(11):741-6. PubMed ID: 12530577
[TBL] [Abstract][Full Text] [Related]
13. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
Lee MH; Reynisdóttir I; Massagué J
Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683
[TBL] [Abstract][Full Text] [Related]
14. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
Gill RM; Slack R; Kiess M; Hamel PA
Exp Cell Res; 1998 Oct; 244(1):157-70. PubMed ID: 9770359
[TBL] [Abstract][Full Text] [Related]
15. Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity.
Ihling C; Technau K; Gross V; Schulte-Mönting J; Zeiher AM; Schaefer HE
Atherosclerosis; 1999 May; 144(1):7-14. PubMed ID: 10381272
[TBL] [Abstract][Full Text] [Related]
16. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
19. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
20. [Cyclin-dependent kinase inhibitory proteins in normal and transformed choroidal melanocytes].
Mouriaux F; Maurage CA; Labalette P; Casagrande F; Malecaze F; Darbon JM
J Fr Ophtalmol; 1999 Apr; 22(3):339-46. PubMed ID: 10337591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
